Disease impact of rheumatoid arthritis in patients not treated with advanced therapies; survey findings from the National Rheumatoid Arthritis Society by Nikiphorou, E et al.
Original article
Disease impact of rheumatoid arthritis in patients
not treated with advanced therapies; survey findings
from the National Rheumatoid Arthritis Society
Elena Nikiphorou1,2, Hannah Jacklin3, Ailsa Bosworth3, Clare Jacklin3,* and
Patrick Kiely 4,5,*
Abstract
Objective. The aim was to reveal the everyday impact of living with RA in people not treated with
advanced therapies (i.e. biologic or targeted synthetic DMARDs).
Methods. People with RA, with disease duration >2 years, not currently treated with advanced thera-
pies, completed an online survey promoted by the National Rheumatoid Arthritis Society. Items cov-
ered demographics, current treatment, RA flare frequency, the Rheumatoid Arthritis Impact of Disease
(RAID) tool and questions reflecting work status and ability. Descriptive and multivariable regression
analyses were performed.
Results. There were 612 responses from patients having a mean age of 59 years, 88% female,
37.7% with disease duration 2–5 years and 27.9% with disease duration 5–10 years. In the last year,
90% reported an RA flare, with more than six flares in 23%. A RAID patient acceptable state was
recorded in 12.4%. Each of the seven domains was scored in the high range by >50% respondents;
74.3% scored sleep problems and 72% fatigue in the high range. A need to change working hours
was reported by 70%. Multivariable analyses revealed that increasing difficulties with daily physical ac-
tivities, reduced emotional and physical well-being in the past week were all significantly associated
with pain, number of flares and ability to cope (P< 0.005). The RAID score was significantly predictive
of the number of flares.
Conclusion. Patients not currently treated with advanced therapies experience profound difficulties
in everyday living with RA, across a broad range of measures. We advocate that patient-reported
measures be used to facilitate holistic care, addressing inflammation and other consequences of RA
on everyday life.
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Key messages
. In established RA patients not on advanced therapies, patient-reported outcomes indicate high levels of suffering.
. The Reumatoid Arthritis Impact of Disease acceptable state is very uncommon.
. High levels of pain, physical disability, sleep difficulties and fatigue are prominent symptoms.
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Introduction
It is widely established that prompt and effective treat-
ment in RA using treat-to-target (T2T) strategies [1]
improves disease outcomes. A range of therapies are
available, including conventional synthetic, targeted syn-
thetic and biologic DMARDs (csDMARDs, tsDMARDs
and bDMARDs, respectively). The principles of T2T in-
corporate treatment escalation, using all available thera-
pies, to achieve and maintain a chosen target, usually
remission or a low disease activity state. A variety of
composite DASs are used, capturing specific objective
measures of inflammation and broad patient-reported
subjective measures of disease impact.
The 28-joint count DAS (DAS28) is used in the UK to
determine eligibility for advanced therapies (tsDMARDs
and/or bDMARDs). However, there is a discrepancy be-
tween the least stringent T2T outcome, a low DAS28
score (3.2; LDAS), and the minimum threshold of a
high DAS28 score (5.1; HDAS) required in some guide-
lines to permit the use of tsDMARDs and/or bDMARDs
[2]. This means that people with moderate disease activ-
ity, between these thresholds (DAS28> 3.2 and <5.1;
mDAS), are not eligible for advanced therapies. Eligibility
is also restricted by the National Institute for Health and
Care Excellence (NICE) biologics pathway in England
and Wales because it limits the maximum number of ad-
vanced therapies a patient can ever receive, denying a
trial of all possible options [2]. Reflecting restrictions
such as these, huge variations are reported in DMARD
use globally [3].
Patients with RA who have not achieved remission, or
at least LDAS, have poor outcomes from the conse-
quences of unsuppressed inflammation on their joints,
including function and requirement for orthopaedic sur-
gery, in addition to the cardiovascular consequences of
accelerated atherogenesis [4–6]. Yet when patients in
the mDAS category receive advanced therapies, they re-
spond as well as those in HDAS and better than those
remaining on csDMARDs [7, 8], in terms of T2T goals of
remission or LDAS and functional outcomes. This con-
firms that substantial benefits can be gained by treating
patients in mDAS with advanced therapies.
Patient and rheumatologist perceptions of what con-
stitutes a successful treatment outcome can differ [9],
with patients using a broader definition than that pro-
vided by DAS28, leading to discordance in the under-
standing of disease severity between patients and
physicians [9]. In this large Korean survey, more than
half of patients with RA thought their disease more se-
vere than their physicians did, with pain, fatigue and
sleep disturbance being some of the factors associated
with discordance. The widely used composite outcome
scores DAS28 and the Simple Disease Activity Index
(SDAI) are derived from observer, patient and laboratory
assessments. Patient assessments in these scores are
limited to a tender joint count and a subjective global
assessment of disease. A variety of composite patient-
reported outcome measures (PROMs) assess the impact
of RA on a broader range of aspects of living with RA,
such as the Rheumatoid Arthritis Impact of Disease
(RAID), the Rheumatoid Arthritis Disease Activity Index
(RADAI) and the Routine Assessment of Patient Index
Data-3 (RAPID3). The RAID score is a patient-derived
differentially weighted seven-item validated and reliable
tool, sensitive to change and EULAR adopted [10]. It is
well correlated with RADAI, patient global measures,
short form-36 (SF-36) physical and mental subscales,
EuroQol-5 Dimension (EQ-5D) health status question-
naire and the DAS28 score [10, 11]. On an individual pa-
tient level, a score below two is deemed a patient
acceptable state [12, 13], and both absolute and relative
minimally clinical important improvements are also de-
fined [13].
This study focuses on the everyday impact of RA in
patients not receiving advanced therapies with
tsDMARDs and/or bDMARDs. It aims to assess in detail
a wide range of aspects of quality of life and everyday
living using the RAID score and other measures of the
impact RA. The work has been instigated by the
National Rheumatoid Arthritis Society (NRAS; https://
www.nras.org.uk/), the UK RA patient organization.
Methods
Survey design and dissemination
Patients with RA were invited by NRAS to complete a
survey (available from NRAS on request). This was
hosted using the NRAS Health-Unlocked online peer
support forum and shared more widely through NRAS
social media channels, including Facebook, Instagram,
LinkedIn and Twitter. A landing page explained the ratio-
nale behind the survey, emphasizing the aim to under-
stand the experiences of patients of living with RA. This
was followed by screening questions to identify the tar-
get population based on current therapies.
Target population
The target population was people with RA, >16 years of
age, with a disease duration of 2 years and living in
the UK. Included patients were allowed to be on analge-
sics, NSAIDs, CSs and csDMARDs but not on advanced
therapies, defined as bDMARDs and tsDMARDs.
Survey components
Items recorded sociodemographic information, including
age, gender, ethnicity, highest educational achievement
and employment status. RA-specific information in-
cluded disease duration, current therapies and access
to advanced therapies.
The frequency of RA flares in the last year was
recorded, based on the definition: an episode of in-
creased RA disease activity accompanied by worsening
symptoms, functional impacts, and clinical indicators of
sufficient magnitude and duration to place individuals at
greater risk of joint damage and poorer outcomes when
left untreated.
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The impact of RA on quality of life in the last week
was assessed by completion of the RAID patient-
reported outcome score covering seven domains: pain,
functional disability, fatigue, sleep, coping/self-efficacy,
physical and emotional well-being. Each of the seven
domains is scored on an 11-integer numerical rating
scale (NRS), with 0 representing a good low activity
score and 10 a high severe activity score. A patient ac-
ceptable state is defined as a RAID score of <2. In the
absence of guidance, we arbitrarily classified the NRS
scores for each individual domain into the following
ranges (low range 0–<5, high range 5, mild 0–2 and
severe 8–10) to gain an idea of which domains scored
particularly poorly or well.
Difficulties at work were measured using a selection
of questions extracted from the Work Productivity and




Descriptive data analyses were undertaken after data
collection, followed by univariable and multivariable re-
gression analyses. Independent variable selection for
multivariable model building was based on their face va-
lidity for prediction of dependent variables and consider-
ations of correlational coefficients, significance levels
and collinearity. Age and gender were maintained in the
models as an a priori decision. Independent variable in-
clusion in logistic backwards stepwise regressions (as
informed by univariable analyses) was conducted to
examine associations with key PROMs. Multivariable re-
gression models were created separately for the follow-
ing dependent variables: pain in the last week, ability to
cope with their RA in the last week, and the number of
RA flares experienced in the past 12 months. The SPSS
statistical package 26 (SPSS, Chicago, IL, USA) was
used for all data analyses (https://www.ibm.com/sup-
port/pages/downloading-ibm-spss-statistics-26).
Results
Six hundred and twelve patients completed the survey.
The mean age was 59 years, 88% were female and
98.5% were of White ethnicity. RA disease duration was
2–5 years in 37.7%, 5–10 years in 27.9% and >10 years
in 34.2%. Full sociodemographic characteristics are
shown in Table 1.
RA treatment
Five hundred and twenty-nine patients (86.4%) were tak-
ing at least one csDMARD, and 15.4% were on CSs.
csDMARDs were used as monotherapy in 262 patients
(42.8%) and as combination therapy in 267 patients
(43.6%). The majority of patients were on MTX (61%), fol-
lowed by HCQ (37%). Other medication included SSZ
(30%), LEF (9%) and AZA (0.5%). The most frequent
combination csDMARD therapy regimen was MTX with
HCQ (n¼ 151, 25%), followed by MTX and SSZ (n¼ 95,
16%).
Most respondents (76%) indicated that advanced
therapies had not been offered or discussed with them.
Of these, 8% reported not being eligible for these thera-
pies. 3% reported that they had experienced side
effects, implying previous use of at least one advanced
therapy, and only 0.3% reported that they were not on
advanced therapies because they were in remission.
RA flares
In the last 12 months, 140 (23%) respondents indicated
having experienced six or more flares, 111 (18%)
reported three flares, and 60 (10%) indicated that they
had experienced no flares. Of those who had experi-
enced flares, 215 (39%) indicated that, on average, a
flare lasted 3–7 days, and 73 (13%) indicated that it
lasted for >5 weeks.
Impact of disease in the last week
Responses to all seven RAID domains were completed
in the majority of cases (n¼ 587), with one domain miss-
ing in 24 additional cases. The missing domain was
emotional well-being in all 24 cases and was substituted
with the mean of the submitted responses to the other
six domains. A total RAID score was therefore calcu-
lated for 611 respondents. The mean was 4.79 (S.D.
2.04, range 0.24–9.10). A RAID score <2, deemed a pa-
tient acceptable state [12, 13], was recorded in 12.4%
of participants.
Table 2 shows, for each domain, the proportion of
respondents scoring low range (<5), high range (5),
mild (0–2) and severe [8–10] scores. In each of the
seven RAID domains, >50% of respondents recorded a
score in the high range in the last week. Sleep and fa-
tigue were the domains with the highest proportion of
respondent scores in the high range and severe catego-
ries, with 74.3%/40.8% and 72%/38.7% of respondents
scoring in these categories, respectively. Ability to cope
was the lowest scoring domain, with least disability
among respondents; however, even here 51.2% scored
in the high range and only 28.9% in the mild range.
The full spread of scores in each domain is shown in
Table 3.
Impact on occupation
A total of 371 respondents answered questions on cur-
rent employment. Fifty-seven of these (15%) reported
7 days off work in the last 6 months. However, 427
individuals responded to a question assessing whether
they had had to change their working hours owing to
their condition, indicating that a larger number of partici-
pants had been employed at some point since RA diag-
nosis. Of these, 298 (70%) indicated that their RA had
caused them to change their working hours.
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TABLE 1 Sociodemographic characteristics of individuals participating in the survey
Characteristic Value [n (%) or mean (S.D.)] Missing [n (%)]
Age, years, mean (S.D.) 59 (11.84)
Range: 69 (minimum ¼ 19, maximum ¼ 88)
N/A
Gender, n (%) Female, 540 (88.2)
Male, 68 (11.1)
4 (0.7%)










University education/professional/vocational equivalents 262 (42.8) N/A
A levels or equivalent 60 (9.8)
GCSE/O level grade or equivalent 108 (17.6)
Vocational, NVQ, BTEC or equivalent 91 (14.9)
No qualifications 57 (9.3)
Other/prefer not to say 34 (5.6)
Work, n (%)
Employed 1–39 h per week 188 (30.7) N/A
Employed 40 h per week 58 (9.5)
Not employed or seeking work 49 (8.0)
Job seeking 10 (1.6)
Disabled and not able to work 79 (12.9)
Retired 228 (37.3)
Geographical spread, n (%)
Southern England
(includes London SHA, South Central SHA, South East
Coast SHA, South West SHA)
228 (37.3) 1 (0.2)
Northern England




(includes East & West Midlands SHA, East of England SHA)
155 (25.3)
Wales 26 (4.2)
Northern Ireland 10 (1.6)
Scotland 60 (9.8)
aIncludes mixed White and Asian, and any other mixed background. bIncludes Black/Black British-Caribbean. cIncludes
Asian/Asian-British, Asian/Asian British-Pakistani, and any other Asian background. SHA Strategic Health Authority.
TABLE 2 Summary scores across seven patient-reported outcomes in the past week








RAID total score 50.2 49.8 12.4a 4.6
Pain 40.9 59.1 19.4 16.6
Functional disability 40.7 59.3 24.1 21.0
Fatigue 28.0 72.0 14.5 38.7
Sleep 25.7 74.3 11.3 40.8
Physical well-being 36.5 63.5 17.8 16.9
Emotional well-being 44.8 55.2 24.1 20.7
Coping 48.8 51.2 28.9 12.6
aPercentage of respondents with Rheumatoid Arthritis Impact of Disease (RAID) total score 0–<2, defined as a patient ac-
ceptable state.
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TABLE 3 Participant reporting of key RA symptoms experienced in the past week
Pain in the last week (range 1–10, with 10 being
indicative of extreme levels of pain)
Difficulties doing daily physical activities in the last
week (range 1–10, with 10 being indicative of extreme
difficulties in doing daily physical activities)
Scale Frequency Valid percentage Scale Frequency Valid
percentage
0 ¼ no pain 30 4.9 0 ¼ no difficulties 50 8.2
1 40 6.5 1 44 7.2
2 49 8.0 2 53 8.7
3 67 10.9 3 54 8.8
4 65 10.6 4 48 7.8
5 71 11.6 5 75 12.3
6 95 15.5 6 81 13.2
7 94 15.4 7 79 12.9
8 61 10.0 8 69 11.3
9 17 2.8 9 25 4.1
10 ¼ extreme
pain
23 3.8 10 ¼ extreme
difficulties
34 5.6
Missing – – Missing – –
Total 612 100.0 Total 612 100.0
Score < 5 251 40.9 Score < 5 249 40.7
Score  5 361 59.1 Score  5 363 59.3
Fatigue in the last week (range 1–10, with 10 being
indicative of being totally exhausted)
Sleep difficulties in the last week (range 1–10, with 10
being indicative of extreme difficulties sleeping in the
last week)
Scale Frequency Valid percentage Scale Frequency Valid
percentage
0 ¼ no fatigue 26 4.2 0 ¼ no difficulty 0 0.0
1 24 3.9 1 34 5.6
2 39 6.4 2 35 5.7
3 35 5.7 3 34 5.6
4 48 7.8 4 54 8.8
5 56 9.2 5 55 9.0
6 51 8.3 6 59 9.6
7 96 15.7 7 91 14.9
8 108 17.6 8 89 14.5
9 66 10.8 9 53 8.7
10 ¼ totally
exhausted
63 10.3 10 ¼ extreme
difficulties
108 17.6
Missing – – Missing – –
Total 612 100.0 Total 612 100.0
Score < 5 172 28.0 Score < 5 157 25.7
Score  5 440 72.0 Score  5 455 74.3
Physical well-being in the last week (range 1–10, with 10
being indicative of being very bad)
Emotional well-being in the last week (range 1–10, with
10 being indicative of very bad)
Scale Frequency Valid percentage
(n 5 611)
Scale Frequency Valid percent-
age (n 5 586)
0 ¼ very good 32 5.2 0 ¼ very good 49 8.4
1 34 5.6 1 40 6.8
2 43 7.0 2 52 8.9
3 58 9.5 3 66 11.3
4 56 9.2 4 55 9.4
5 116 19.0 5 72 12.3
(continued)
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Stepwise backwards regression analyses
In multivariable analyses (Table 4), for every unit in-
crease in the scores of daily physical activities and of
emotional well-being in the past week, there was a sig-
nificant increase in pain experienced in the past week
and worsening in the ability to cope (P< 0.005).
Increasing difficulties with daily physical activities and
reduced emotional and physical well-being in the past
week were all significantly associated with all three out-
comes of pain, number of flares (in the last 12 months)
and ability to cope (P< 0.005). The RAID score was
significantly predictive of the number of flares in age-
and gender-adjusted models, whereby for every unit
increase in the score, there was an increase in the
number of flares by 0.5 units (b-co-efficient 0.52; 95%
CI 0.45–0.58).
Discussion
This survey, led by the NRAS, has focused on the im-
pact of disease in patients with established RA currently
not receiving advanced therapies. It shows that RA
flares are extremely common, with 90% of patients
experiencing at least one flare and nearly a quarter
reporting six or more flares in the last year. Only 12.4%
of respondents were currently in a patient acceptable
state, as defined by a total RAID score less than two.
The high impact of RA on everyday life is further empha-
sized by the finding that in all seven domains, >50%
respondents recorded scores in the high range, indicat-
ing a significant burden in the last week. This is sup-
ported by impact on work data from the survey, with
70% of respondents reporting a change in working
hours owing to their RA. Difficulties with daily physical
activities and worsened physical and emotional well-
being were significantly associated with higher pain, a
greater number of flares and worsened ability to cope.
Thus, across all assessed PROMs, RA patients currently
not taking advanced therapies experience an inter-
related burden of adverse outcomes from their disease.
These findings argue for a detailed interpretation of
DAS28 or SDAI scores when considering treatment es-
calation to achieve T2T goals. Unsuppressed
TABLE 3 Continued
Physical well-being in the last week (range 1–10, with 10
being indicative of being very bad)
Emotional well-being in the last week (range 1–10, with
10 being indicative of very bad)
Scale Frequency Valid percentage
(n 5 611)
Scale Frequency Valid percent-
age (n 5 586)
6 74 12.1 6 54 9.2
7 95 15.5 7 76 13.0
8 69 11.3 8 70 11.9
9 15 2.5 9 23 3.9
10 ¼ very bad 19 3.1 10 ¼ very bad 29 4.9
Missing 1 – Missing 26 –
Total 612 100.0 Total 612 100.00
Score < 5 223 36.5 Score < 5 262 44.8
Score  5 388 63.5 Score  5 324 55.2
Ability to cope with their RA in the last week (range 1–10, with 10 being
indicative of people feeling their ability to cope is not good)
Scale Frequency Valid percentage (n 5 611)










10 ¼ very poorly 16 2.6
Missing 1 –
Total 612 100.0
Score < 5 299 48.8
Score  5 312 51.2
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inflammation, and its consequences for individual com-
ponent scores within DAS28/SDAI, should be addressed
with an escalation of immune suppression. However, a
high patient global score or tender joint count might re-
flect factors other than inflammation. Composite
PROMs, such as RAID, provide a detailed analysis of
the breadth and severity of the impact of RA on
patients’ everyday lives. When a failure to reach a RDAS
or LDAS T2T goal is driven by non-inflammatory factors,
it would be appropriate to target high-scoring domains
from the responses to PROMs, with interventions such
as cognitive behavioural therapy for fatigue, poor sleep
and mental health or neurogenic agents for pain sensiti-
zation. A positive impact on these will then be reflected
in a lower patient global score and a higher likelihood of
achieving the desired DAS28 or SDAI T2T goal. There is
also scope for greater use of non-pharmacological inter-
ventions in patients in remission. A study of 140 patients
with early RA who had achieved rapid and sustained
remission within a year revealed that one in five had dis-
cordant poorly controlled pain and/or fatigue [14].
Likewise, of 134 RA patients with established disease in
remission or low disease activity, RAID was at least two
in 51.5% [15]. In a holistic model of care, these impor-
tant measures of quality of life should be recorded and
addressed, as advocated by the NICE [16]. In support of
our findings, recent data from the Rheumatoid Arthritis
Medication Study (RAMS) demonstrate that despite a
‘satisfactory’ rating of their condition, early RA patients
with high PROM scores are less likely to respond to
therapy, calling for high vigilance to optimize care and
outcomes [17].
Although this survey specifically targeted patients not
on advanced tsDMARDs and/or bDMARDs, it was not
possible to determine the current DAS28 score or the
treatment history for each patient. The minimum disease
duration of 2 years means that it is likely that those with
HDAS (i.e. DAS28> 5.1) up to that time point would al-
ready have been treated with advanced therapies and
therefore excluded from the survey. Some might have
been in the HDAS range and not on advanced therapies
because they were about to start or were in transition to
a second or third tsDMARD or bDMARD. Only 3% indi-
cated previous adverse events in response to
bDMARDs, suggesting very few might have been in
transition between advanced therapies for this reason.
We believe it likely that the majority of respondents had
never received advanced therapies, and in UK practice
this means they would have had a DAS <5.1.
Regardless of the current DAS28 score, our findings
TABLE 4 Multivariable models with pain, number of RA flares and ability to cope as dependent outcomes
Model 1: pain in the
last week
Model 2: number of RA flares
experienced in the last 12 months
Model 3: ability to cope
with their RA in the last week
Independent variable Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI)
n 5 584 n 5 607 n 5 393
Gender 0.120 (0.445, 0.206) 0.040 (0.372, 0.452) 0.039 (0.397, 0.476)
Age 0.009 (0.018, 0.000) 0.009 (0.020, 0.002) 0.020** (0.008, 0.031)
Number of RA flares
experienced in the
last 12 months
0.167** (0.103, 0.230) – –
DMARDs: take LEF – 0.499* (0.053, 0.945) –




0.474** (0.403, 0.545) – 0.323** (0.234, 0.412)
Physical well-being in
the last week
0.188** (0.104, 0.272) 0.154** (0.072, 0.237) 0.206** (0.098, 0.314)
Emotional well-being
in the last week
0.068* (0.129, 0.006) – 0.336** (0.258, 0.414)
Ability to cope with
their RA in the last
week
0.130** (0.056, 0.204) – –
Model information
Model fit 0.000** 0.000** 0.000**
R 0.876 0.574 0.861
R2 0.767 0.329 0.741
Other variables adjusted for in the models included difficulties with working with the hands, DMARD use and feeling that
RA is controlled enough to allow daily life. The R value represents the simple correlation. The R2 value indicates how
much of the total variation in the dependent variables can be explained by the independent variable(s). *P<0.05;
**P<0.005. LEF: leflunomide.
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indicate a very high impact of RA on everyday quality of
life. The dominance of fatigue and sleep domains re-
cording the greatest disability is also supported by pre-
vious studies including patients who were in remission
or LDAS [15, 18–20].
The strengths of this survey are its size, with 612
respondents, with age and gender as expected for an
established RA population, and its ecological validity,
with broad geographical reach across England, making
the findings largely generalizable, although Northern
Ireland, Scotland and Wales were under-represented.
The frequency of csDMARD use is reflective of common
treatment approaches in the UK. Limitations of this
study include the survey-based nature of data collection
at a single time point, with potential selection bias, eth-
nicity being primarily White, and the high proportion of
female respondents. Although the last of these is
expected in RA, the results are limited in generalizability
of findings to other ethnic groups and males. The dis-
proportionally high number of respondents achieving the
highest levels of education (university degree or similar)
will have introduced bias. These respondents are more
likely to understand complex information, access resour-
ces for self-help and adhere to therapies, thus maximiz-
ing opportunities to maintain their quality of life. This
means that our findings are a likely to be under-
estimation of the burden of RA across all patient groups.
The strict eligibility criteria for advanced therapies in the
UK might have influenced the impact of disease on our
respondents, because all had established RA for
2 years, and >10 years in 34%. It would be interesting
to reproduce our findings in similar people with estab-
lished RA not on advanced therapies from countries
where the disease activity threshold to escalate therapy
is lower. Finally, identification of flares by subjective re-
port might have been biased if there was difficulty in
distinguishing an RA flare from other causes of short-
term pain, such as intercurrent infection or a loss of
long-term control of RA.
In conclusion, this study highlights the extensive impact
that RA exerts on everyday quality of life in patients not
treated with advanced therapies, extending previous work
demonstrating the poor long-term function and orthopaedic
outcomes in similar patients. PROMs represent a valuable
source of information to facilitate holistic care, combining
suppression of inflammation with other interventions to
minimize the impact of disease on important aspects of
daily life, including fatigue, sleep and well-being. We advo-
cate routine collection of PROMs in daily practice to pro-
vide insights into disease severity and impact otherwise
not captured in composite scores, such as DAS28.
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